1. Aghamollaei T, Eftekhar H, Mohammad K, Nakhjavani M, Shojaezadeh D, Ghofranipour F, et al. Effects of a health education program on behavior, HBA1c and health-related quality of life in diabetic patients. Acta Medical Iranica 2005; 43(2): 89-94.

2. Tsirona S, Katsaros F, Bargiota A, Polyzos SA, Arapoglou G, Koukoulis GN. Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. Hormones. 2016 Jan-Mar 15 (1):88-98. [DOI:10.14310/horm.2002.1662]

3. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999 Jul;145 (1):33-43. [DOI:10.1016/S0021-9150(99)00011-8]

4. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2006 Aug;29 (8):1963-72. [DOI:10.2337/dc06-9912]

5. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan;348 (5):383-93. [DOI:10.1056/NEJMoa021778]

6. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes care. 2013 Apr;36 (4):1033-46. [DOI:10.2337/dc12-2625]

7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2011 Jun; 34(Suppl 1): S11–S61. [DOI:10.2337/dc11-S011]

8. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 Jun 2;330 (7503):1304-5. [DOI:10.1136/bmj.38415.708634.F7]

9. Correia S, Carvalho C, Santos MS, Seiça R, Oliveira CR, Moreira PI. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini reviews in medicinal chemistry. 2008 Nov 1;8 (13):1343-54. [DOI:10.2174/138955708786369546]

10. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb;27 (4):504-10. [DOI:10.1200/JCO.2008.18.6130]

11. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108 (8):1167-74. [DOI:10.1172/JCI13505]

12. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007 Nov-Dec;13 (6):527-37. [DOI:10.1093/humupd/dmm026]

13. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016 Jun;164 (11):740-51. [DOI:10.7326/M15-2650]

14. Eli Lilly and company. FDA approves first-in-class Glyxambi (empagliflozin/linagliptin) tablets for adults with type 2 diabetes. Press release. February 2 [Online]. Available: http://lilly.mediaroom.com/ index.php?s=9042&item=137386. Accessed February 25, 2015.

15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015 Jan;38 (1):140-9. [DOI:10.2337/dc14-2441]

16. DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care. 2015 Mar; 38 (3):384-93. [DOI:10.2337/dc14-2364]

17. Singh‐Franco D, McLaughlin‐Middlekauff J, Elrod S, Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. Diabetes Obes Metab. 2012 Aug;14 (8):694-708. [DOI:10.1111/j.1463-1326.2012.01586.x]

18. Terawaki Y, Nomiyama T, Takahashi H, Tsutsumi Y, Murase K, Nagaishi R, et al. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2015 May;7:44. [DOI:10.1186/s13098-015-0043-2]

19. Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc. 2010 Dec; 85 (12 Suppl): S5-S14. [DOI:10.4065/mcp.2010.0467]

20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine. 2009 Jul;6 (7):e1000100. [DOI:10.1371/journal.pmed.1000100]

21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct;343:d5928. [DOI:10.1136/bmj.d5928]

22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17 (1):1-12. [DOI:10.1016/0197-2456(95)00134-4]

23. Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012 Sep;28 (9):1465-74. [DOI:10.1185/03007995.2012.714360]

24. Ingellheim B. Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design [Online]. 2013: Available from:https://clinicaltrials.gov/ct2/show/ NCT00798161?term=NCT00798161&rank=1.

25. Boehringer I, Elil, & Company. Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients ] Online].2015: Available from:https://clinicaltrials.gov/ct2/show/NCT01708902?term=NCT01708902&rank=1.

26. Boehringer I, Study CHair & Boehringer I. Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients, NCT00328172 [Online]. 2014:Available from: https://clinicaltrials.gov/ct2/show/NCT00328172?term=NCT00328172&rank=1.

27. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes Obes Metab. 2011 Jul;13 (7):653-61. [DOI:10.1111/j.1463-1326.2011.01391.x]

28. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011 Mar;13 (3):258-67. [DOI:10.1111/j.1463-1326.2010.01350.x]

29. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes Obes Metab. 2011 Jan;13 (1):65-74. [DOI:10.1111/j.1463-1326.2010.01326.x]

30. Weinstein JN, Tosteson TD, Lurie JD, Tosteson AN, Hanscom B, Skinner JS, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA. 2006 Nov;296 (20):2441-50. [DOI:10.1001/jama.296.20.2441]